Sorrento Therapeutics, Inc. (SRNEQ)

Market Cap	16.54M
Revenue (ttm)	64.27M
Net Income (ttm)	-548.10M
Shares Out	551.28M
EPS (ttm)	-1.12
PE Ratio	n/a
Forward PE	1.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,730
Open	0.0200
Previous Close	0.0290
Day's Range	0.0200 - 0.0310
52-Week Range	0.0010 - 0.4190
Beta	2.29
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About SRNEQ

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispe...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 949
• Stock Exchange: OTCMKTS
• Ticker Symbol: SRNEQ

Financial Performance

In 2022, SRNEQ's revenue was $62.84 million, an increase of 18.78% compared to the previous year's $52.90 million. Losses were -$572.84 million, 33.7% more than in 2021.